Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 5/20 | 0.56 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | ABL2 | P42684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12100759 | 0.81 | MAP4K4 (0.46) | MAP4K4ADORA2A | |
| SCHEMBL23319557 | 0.79 | MAP4K4 (0.45) | MAP4K4TDO2ADORA2AADORA1NPC1 | |
| SCHEMBL17555726 | 0.79 | FYN (0.49) | MAP4K4FYN | |
| SCHEMBL11901043 | 0.79 | MAP4K4 (0.48) | MAP4K4ADORA2AADORA1LRRK2FYN | |
| SCHEMBL11901650 | 0.78 | MAP4K4 (0.46) | MAP4K4TDO2LRRK2KDRNPC1 | |
| SCHEMBL15954236 | 0.78 | MKNK1 (0.41) | MAP4K4DHFRNUDT1LRRK2 | |
| SCHEMBL1165179 | 0.77 | GSK3B (0.47) | MAP4K4TDO2ADORA2AADORA1LRRK2 | |
| SCHEMBL31728471 | 0.76 | MAP4K4 (0.53) | MAP4K4DHFRNUDT1TDO2ADORA2A | |
| SCHEMBL5223234 | 0.76 | DHFR (0.51) | MAP4K4DHFRNUDT1TDO2ADORA2A | |
| SCHEMBL4938505 | 0.76 | DYRK1A (0.54) | MAP4K4TDO2ADORA2AADORA1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103476767-B | Heterocyclic compounds as PI3 kinase inhibitors | HOFFMANN LA ROCHE | 2015-06-10 | — | — | CN | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| CN-103476767-A | Heterocyclic compounds as PI3 kinase inhibitors | HOFFMANN LA ROCHE | 2013-12-25 | — | — | CN | disclosed |
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | MAP4K4 191/4885DHFR 1934/4885NUDT1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.